OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Franke on Treatment Options for NSCLC Expressing Uncommon EGFR Mutations

April 10th 2023

Aaron J. Franke, MD, MS, discusses treatment options for patients with uncommon EGFR mutations in non–small cell lung cancer.

Dr Foote on the Use of Tucatinib Plus Trastuzumab in HER2-Amplified mCRC

April 10th 2023

Micheal Foote, MD, discusses the use of tucatinib plus trastuzumab compared with chemotherapy in the management of HER2-amplified metastatic colorectal cancer.

Dr Fenton on Trastuzumab Deruxtecan Vs Trastuzumab Emtansine in HER2+ Breast Cancer

April 7th 2023

Mary Anne Fenton, MD, discusses findings from the phase 3 DESTINY-Breast03 trial in patients with metastatic, HER2-positive breast cancer.

Dr Deol on CAR T-cell Therapy in Multiple Myeloma

April 7th 2023

Abhinav Deol, MD, discusses the efficacy and durability of CAR T-cell therapies in patients with multiple myeloma.

Dr Zonder on the Promise of Talquetamab and Cevostamab in R/R Multiple Myeloma

April 7th 2023

Jeffery Zonder, MD, discusses the derived benefit that has been derived from talquetamab and cevostamab in patients with relapsed/refractory multiple myeloma.

Dr Ryan on the Evolution of the Treatment Landscape in RCC

April 7th 2023

Christopher W. Ryan, MD, professor of medicine School of Medicine at the Oregon Health & Science University, discusses the evolution of therapeutic treatment approaches across the management treatment landscape of renal cell carcinoma.

Dr Epstein-Peterson on the Use of CAR T-Cell Therapy in MCL

April 7th 2023

Zachary Epstein-Peterson, MD, discusses the use of CAR T-cell therapy in mantle cell lymphoma and highlights questions that remain to be answered within the treatment landscape.

Dr Goldberg on Potential Strategies to Overcome Osimertinib Resistance in EGFR+ NSCLC

April 7th 2023

Sarah Goldberg, MD, MPH, discusses potential strategies to overcome osimertinib resistance in EGFR-positive metastatic non–small cell lung cancer.

Dr Sikov on the Use of CDK4/6 Inhibitors in the First-line Treatment of ER+/HER2- Breast Cancer

April 7th 2023

William M. Sikov, MD, discusses the negative outcome seen with palbociclib in the phase 3 PALOMA-2 trial, and compares this to data on other CDK4/6 inhibitors in the first-line treatment of estrogen receptor–positive, HER2-negative breast cancers.

Dr Jain on the Use of Haploidentical Donors in Myelofibrosis

April 6th 2023

Tania Jain, MBBS, discusses the use of haploidentical donors in myelofibrosis.

Dr Atkins on the Rationale of Investigating Nivolumab/Ipilimumab in RCC

April 6th 2023

Michael B. Atkins, MD, discusses the rationale for launching the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.

Dr Hays on Treating Patients With HER2+ CRC

April 6th 2023

John L. Hays, MD, PhD, discusses advances in treating patients with HER2-positive colorectal cancer.

Dr Callander on Investigational Maintenance Regimens in Multiple Myeloma

April 6th 2023

Natalie S. Callander, MD, discusses the significance of the phase 3 ATLAS, phase 2 FORTE, and phase 2 MASTER trials in patients with multiple myeloma.

Dr Kuykendall on Emerging Therapies in Systemic Mastocytosis

April 6th 2023

Andrew Kuykendall, MD, discusses agents currently in development for patients with systemic mastocytosis and how these investigational therapies may fit into the overall treatment paradigm for this disease.

Dr Graff on Data From HER2CLIMB Exploratory Analysis in HER2+ Breast Cancer With Brain Metastases

April 6th 2023

Stephanie L. Graff, MD, discusses data from an exploratory analysis of patients with HER2-positive breast cancer and brain metastases enrolled to the phase 2 HER2CLIMB study, and emphasizes the need for such research efforts to move the needle forward for this population.

Dr Epstein-Peterson on the Treatment of Transplant-Eligible and -Ineligible Patients with MCL

April 6th 2023

Zachary Epstein-Peterson, MD, discusses available treatment approaches for patients with mantle cell lymphoma who are transplant eligible or ineligible.

Dr Kuykendall on AEs With Midostaurin and Avapritinib in Advanced Systemic Mastocytosis

April 5th 2023

Andrew Kuykendall, MD, discusses the occurrence and management of adverse effects associated with midostaurin and avapritinib in patients with advanced systemic mastocytosis.

Dr Kuykendall on Molecular Testing in Systemic Mastocytosis

April 5th 2023

Andrew Kuykendall, MD, discusses the importance of testing for mutations in KIT and other genes in patients with systemic mastocytosis.

Dr Shah on the Investigation of LV20.19 CAR in MCL

April 5th 2023

Nirav N. Shah, MD, discusses the investigation of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.

Dr Dawson on Palliative Radiotherapy in Symptomatic HCC or Liver Metastases

April 5th 2023

Laura Dawson, MD, FRCPC, discusses the investigation of palliative radiotherapy for patients with symptomatic hepatocellular carcinoma or liver metastases.